UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$579.67 USD
+5.43 (0.95%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $579.01 -0.66 (-0.11%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$579.67 USD
+5.43 (0.95%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $579.01 -0.66 (-0.11%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, UnitedHealth Group (UNH) closed at $226.79, marking a -1.66% move from the previous day.
Stock Market News For Sep 3, 2019
by Zacks Equity Research
Markets closed higher on Friday as positive developments on the trade war front boosted the investor sentiment.
Mednax Collaborates With Northern Indiana Neonatal Associates
by Zacks Equity Research
Mednax (MD) joins forces with Northern Indiana Neonatal Associates in Fort Wayne to enhance its neonatal services.
UnitedHealth Group (UNH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed at $230.62 in the latest trading session, marking a +1.44% move from the prior day.
Here's Why Cigna (CI) is an Attractive Investment Option Now
by Zacks Equity Research
Cigna (CI) remains well poised for growth on the back of Express Scripts acquisition.
Magellan Healths Growth Measures Aid Investors' Confidence
by Zacks Equity Research
Magellan Health's (MGLN) initiatives to add new business and reduce cost of goods sold aid growth.
Humana Ties Up to Enhance Facilities for Members in Michigan
by Zacks Equity Research
Humana (HUM) teams up with McLaren Physician Partners to provide in-network access to its members in Michigan.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
UnitedHealth Group (UNH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, UnitedHealth Group (UNH) closed at $240.39, marking a +0.1% move from the previous day.
Is UnitedHealth Group (UNH) A Great Pick for Value Investors?
by Zacks Equity Research
Is UnitedHealth Group Holdings (UNH) a great pick from the value investor's perspective right now? Read on to know more.
UnitedHealth (UNH) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc Up 33% Year to Date: Will the Momentum Continue?
by Zacks Equity Research
Teladoc's (TDOC) vast business presence in the growing telehealth industry with many deal wins and international expansion should drive long-term growth.
Why Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Banking on its solid second-quarter results and a growing bottom line, Universal Health (UHS) holds potential to garner benefits for investors.
Zacks Industry Outlook Highlights: Joint, Anthem, Centene and UnitedHealth
by Zacks Equity Research
Zacks Industry Outlook Highlights: Joint, Anthem, Centene and UnitedHealth
Outlook for Health Insurance Industry Looks Sanguine
by Sapna Bagaria
Consolidation, increasing senior population, technological advancements and development of supplementary healthcare businesses poise the health insurance industry for secular growth.
Buy CVS Health (CVS) Ahead of Q2 Earnings?
by Christopher Vargas
CVS Health (CVS) will be reporting their second quarter before the opening bell on Wednesday.
Community Health's (CYH) Q2 Loss Widens, Revenues Fall Y/Y
by Zacks Equity Research
Community Health's (CYH) second-quarter results suffer due to lower admissions.
Tenet Healthcare (THC) Q2 Earnings Top Estimates & Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings gain on the back of its Hospital and Other segment and volume growth.
Trade and Currency Concerns Put Pressure on Equities
by David Borun
A busy week of data and a Fed meeting was dominated by China trade issues
Ensign Group's (ENSG) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter earnings gain traction from improved revenues.
MEDNAX's (MD) Earnings Beat Estimates in Q2, Decrease Y/Y
by Zacks Equity Research
Mednax's (MD) Q2 gains on revenue growth, partly offset by rise in expenses.
DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.
Cigna (CI) Beats on Q2 Earnings and Revenues, Guides Up
by Zacks Equity Research
Cigna's (CI) Q2 earnings gain from the acquisition of Express Scripts, completed in December 2018.
Humana's (HUM) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Humana's (HUM) second-quarter earnings gain from Medicare Advantage membership growth.
Molina Healthcare (MOH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter earnings trump estimates on the back of lower expenses and the Meridian buyout.